Publication Name	World Journal of Hepatology
Manuscript ID	24505
Country	Pakistan

Received	2016-01-26 10:15
Peer-Review Started	2016-01-27 09:07
To Make the First Decision	2016-03-09 10:02
Return for Revision	2016-03-10 09:17
Revised	2016-03-13 22:53
Second Decision	2016-04-07 12:13
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-04-18 11:45
Articles in Press	2016-04-18 11:45
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-04-19 16:11
Publish the Manuscript Online	2016-05-12 10:37

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Randomized Clinical Trial
Article Title	Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial
Manuscript Source	Invited Manuscript
All Author List	Zaigham Abbas, Mohammad Sadik Memon, Muhammad Amir Umer, Minaam Abbas and Lubna Shazi
Funding Agency and Grant Number
Corresponding Author	Dr. Zaigham Abbas, FCPS, FRCP, Department of Gastroenterology, Ziauddin University Hospital, Shahrah-e-Ghalib, Karachi 74400, Pakistan. drzabbas@gmail.com
Key Words	Hepatitis D; Entecavir; Hepatitis B surface antigen; Pegylated interferon; Hepatitis D virus RNA; Treatment
Core Tip	Chronic hepatitis D is a difficult to treat infec-tion. Six months post treatment response is seen only in one quarter of the patients treated with pegy-lated interferon alfa (PEG-IFNα). In an attempt to improve the response of PEG-IFN, we combined entecavir. This is the first study to evaluate the efficacy of PEG-IFN with entecavir compared to PEG-IFN alone for the treatment of hepatitis D infection. Our study showed that the com-bination treatment did not have any additional benefit in terms of hepatitis D virus RNA suppression and hepatitis B surface antigen reduction as compared to PEG-IFN alone.
Publish Date	2016-05-12 10:37
Citation	Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol 2016; 8(14): 625-631
URL	http://www.wjgnet.com/1948-5182/full/v8/i14/625.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i14.625

Full Article (PDF)	WJH-8-625.pdf
Full Article (Word)	WJH-8-625.doc
Manuscript File	24505-Review.docx
Answering Reviewers	24505-Answering reviewers.pdf
Audio Core Tip	24505-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	24505-Conflict-of-interest statement.pdf
Copyright License Agreement	24505-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20160125155135.pdf
Institutional Review Board Approval Form or Document	24505-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	24505-Language certificate.pdf
Peer-review Report	24505-Peer-review(s).pdf
Scientific Misconduct Check	24505-Scientific misconduct check.pdf
Scientific Editor Work List	24505-Scientific editor work list.pdf